Search PubMed⌕ Search

Biomedical subjects

M Marcucci

Publications and source records attributed to M Marcucci.

At least 55 records · Page 3Linked to original sources
PubMed1982

[Leukoplakia].

Explore the source record for details and available documents.

Humans↗
PubMed1979

Evaluation of antihemorrhagic activity of V. F.

In the prophylaxis of surgical interventions performed in the Dental Clinic for dental avulsions under general anesthesia, the V. F. (peptides deriving from the enzymatic degradation of bovine Factor VIII) has been shown to be particularly active in the reduction of the quantity of blood lost per tooth, corresponding to a reduction in blood loss of an average of 40% to 45%. The "double blind" experiment confirmed a significant hemostatic capacity of the preparation. V. F. in extremely small doses (1 mg/day) divided into two daily, oral administrations, isn't toxic, isn't habit forming and doesn't provoke immunological reactions. On the basis of its positive characteristics (diminution of blood lost without alteration of the parameters of coagulation or platelet aggregation), V. F. seems to be the preparation of choice for the treatment of hemorrhagic diathesis not accompanied by coagulation defect, and also as a preventive measure in minor surgical interventions where small vessels are involved and hemostasis cannot be achieved surgically.

Clinical Trials as Topic↗
PubMedDate not supplied

[IL-6, p53 and proto-oncogene c-myc play different roles as biological markers of plasma cell dyscrasias].

PURPOSE: To determine the role of serum levels of IL-6 and p53 mutant protein as well as of c-myc proto-oncogene alterations: a) in discriminating between benign (MGUS) and malignant Plasma cell dyscrasias (Multiple and Microsecreting Myeloma, Plasmocytoma); b) in monitoring the clinical course of malignant forms of this disease. PATIENTS AND METHODS: Eighty-eight patients affected by Plasma cell dyscrasias (58 MGUS, 24 MM and 6 PLC) entered this study. Using commercially available ELISA kits, serum levels of IL-6 and p53 have been determined in all the patients. In addition, a selected group of patients (n = 30) was also analyzed for structural c-myc gene alterations by Southern blot technique. RESULTS: The results show that, conversely from p53 protein, IL-6 and c-myc gene may represent useful diagnostic markers for discriminating benign from malignant forms of Plasma cell dyscrasia. On the contrary, preliminary findings of the same work indicate a potential role for the mutant p53 protein in monitoring the response to chemotherapy of patients affected by MM or PLM. CONCLUSIONS: Overall, these data suggest that the combined use of IL-6, p53 and c-myc may provide a new approach for a more rational management of Plasma cell dyscrasia patients.

Adult↗